MX2017001656A - Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. - Google Patents

Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.

Info

Publication number
MX2017001656A
MX2017001656A MX2017001656A MX2017001656A MX2017001656A MX 2017001656 A MX2017001656 A MX 2017001656A MX 2017001656 A MX2017001656 A MX 2017001656A MX 2017001656 A MX2017001656 A MX 2017001656A MX 2017001656 A MX2017001656 A MX 2017001656A
Authority
MX
Mexico
Prior art keywords
bruton
tyrosine kinase
kinase inhibitor
inhibitor combinations
inhibitor
Prior art date
Application number
MX2017001656A
Other languages
English (en)
Inventor
Chang Betty
Kuo Hsu-Ping
Cheung Leo
Kang Hsieh Hsin-
Xue Ling
Balasubramanian Siriram
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2017001656A publication Critical patent/MX2017001656A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

En la presente, se divulgan métodos, composiciones y kits para tratar una neoplasia maligna de linfocitos B que comprende la administración de una combinación de un inhibidor de BTK (por ejemplo, ibrutinib) y un inhibidor de PIM. También se divulgan en la presente métodos, composiciones y kits para tratar una neoplasia maligna de linfocitos B resistente a BTK que comprende la administración de una combinación de un inhibidor de BTK (por ejemplo, ibrutinib) y un inhibidor de PIM.
MX2017001656A 2014-08-08 2015-08-06 Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. MX2017001656A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462034997P 2014-08-08 2014-08-08
US201462082972P 2014-11-21 2014-11-21
US201462086162P 2014-12-01 2014-12-01
US201562196251P 2015-07-23 2015-07-23
PCT/US2015/044095 WO2016022853A1 (en) 2014-08-08 2015-08-06 Bruton's tyrosine kinase inhibitor combinations and uses thereof

Publications (1)

Publication Number Publication Date
MX2017001656A true MX2017001656A (es) 2017-07-24

Family

ID=55264587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001656A MX2017001656A (es) 2014-08-08 2015-08-06 Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.

Country Status (10)

Country Link
US (2) US9730938B2 (es)
EP (1) EP3177366A4 (es)
JP (1) JP2017523207A (es)
CN (1) CN106714909A (es)
AU (1) AU2015300966A1 (es)
BR (1) BR112017002232A2 (es)
CA (1) CA2956550A1 (es)
MX (1) MX2017001656A (es)
TW (1) TWI586354B (es)
WO (1) WO2016022853A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
KR20180088926A (ko) 2012-07-24 2018-08-07 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
WO2016071770A2 (en) * 2014-11-05 2016-05-12 Janssen Pharmaceutica Nv Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same
US10966977B2 (en) 2016-05-27 2021-04-06 Tg Therapeutics, Inc. Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
AU2018251898A1 (en) 2017-04-13 2019-10-31 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11389440B2 (en) 2017-10-04 2022-07-19 University Of Maryland, Baltimore County PIM kinase inhibitors in combination with autophagy inhibitors for treatment of cancers
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
CN112584902A (zh) 2018-05-03 2021-03-30 朱诺治疗学股份有限公司 嵌合抗原受体（car）t细胞疗法和激酶抑制剂的组合疗法
CN111053777A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 伊布替尼的药物组合物及其应用
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
JP2022512766A (ja) 2018-10-17 2022-02-07 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
EP3871665A1 (en) 2020-02-28 2021-09-01 Martin-Luther-Universität Halle-Wittenberg Inhibitors of rna-binding proteins as anti-cancer drugs
KR20230054394A (ko) * 2020-08-21 2023-04-24 얀센 파마슈티카 엔.브이. 비정질 형태의 malt1 억제제 및 이의 제형
EP3967307A1 (en) * 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions
CN117320720A (zh) * 2021-03-03 2023-12-29 詹森药业有限公司 使用malt1抑制剂和btk抑制剂的组合疗法
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7832117B2 (en) * 2006-07-17 2010-11-16 Nike, Inc. Article of footwear including full length composite plate
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
EA032463B1 (ru) * 2011-10-19 2019-05-31 Фармасайкликс Элэлси Применение ингибиторов тирозинкиназы брутона (втк)
NZ702548A (en) * 2012-06-04 2015-11-27 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
SG11201408679XA (en) * 2012-06-26 2015-01-29 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors

Also Published As

Publication number Publication date
BR112017002232A2 (pt) 2018-07-24
EP3177366A1 (en) 2017-06-14
US9730938B2 (en) 2017-08-15
AU2015300966A1 (en) 2017-02-16
WO2016022853A1 (en) 2016-02-11
CN106714909A (zh) 2017-05-24
TWI586354B (zh) 2017-06-11
TW201609107A (zh) 2016-03-16
CA2956550A1 (en) 2016-02-11
EP3177366A4 (en) 2018-04-04
US20180071295A1 (en) 2018-03-15
US20160038495A1 (en) 2016-02-11
JP2017523207A (ja) 2017-08-17

Similar Documents

Publication Publication Date Title
MX2017001656A (es) Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2018010484A (es) Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MY190548A (en) Tyrosine kinase inhibitors
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
SG10201902326XA (en) Mk2 inhibitors and uses thereof
MX2022006768A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
MX2018004664A (es) Antagonistas de ep4.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2017002388A (es) Composiciones para fibras de queratina.